文献速递艾滋病与性传播感染

抗逆转录病毒治疗换药后的体重变化:随机临床试验汇总数据

Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究汇总12项前瞻性临床试验,分析病毒学抑制的HIV感染者在换药或维持原方案后的体重变化。换药组48周体重增幅中位数1.6 kg,高于维持组的0.4 kg(P<.0001);从依非韦仑或替诺福韦二吡呋酯换药者体重增加风险最高。

要点

  • 换药后体重增加多发生于换药后前24周,48周时趋于平台。
  • 从EFV或TDF换药者体重增加及≥10%体重增加风险最高。
  • 阿巴卡韦换用TAF的体重增加少于TDF换用TAF。

核心结论

  • 病毒学抑制的HIV感染者换药后普遍出现中度体重增加,多在48周内趋于平台;基线抗逆转录病毒方案可预测换药后体重增加,从EFV和TDF换药者体重增加最多。

研究设计与样本

  • 12项前瞻性随机临床试验的汇总分析,病毒学抑制的HIV感染者随机换药(n=4166)或维持稳定基线方案(n=3150)。

主要发现

  • 换药组48周体重增幅中位数1.6 kg(IQR -.05至4.0),维持组0.4 kg(IQR -1.8至2.4),P<.0001。
  • 体重增加多发生于换药后前24周。
  • 基线特征中仅较年轻年龄和较低基线BMI与任何体重增加或≥10%体重增加相关。
  • 48周时4.6%出现≥10%体重增加(换药组6.4%,维持组2.2%)。
  • 从EFV换用RPV或EVG/c、从TDF换用TAF者≥10%体重增加风险最高;ABC换用TAF的体重增加少于TDF换用TAF,且与≥10%体重增加风险无关。

临床怎么用

  • 对病毒学抑制者换药时应评估体重增加风险,尤其从EFV或TDF换药者,需加强体重监测。

局限性

  • 换药影响体重的生物学机制及临床意义尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We sought to identify factors associated with weight gain in randomized clinical trials of antiretroviral therapy (ART) switch. METHODS: We explored the effects of demographic factors, clinical characteristics, and ART on weight gain in a pooled analysis of 12 prospective clinical trials, wherein virologically suppressed people living with human immunodeficiency virus (PWH) were randomized to switch or remain on a stable baseline regimen (SBR). RESULTS: Both PWH randomized to switch ART (n = 4166) and those remaining on SBR (n = 3150) gained weight. Median weight gain was greater in those who switched (1.6 kg, interquartile range [IQR], -.05 to 4.0 vs 0.4 kg, [IQR], -1.8 to 2.4 at 48 weeks, P < .0001), with most weight gain occurring in the first 24 weeks after switch. Among baseline demographic and clinical characteristics, only younger age and lower baseline body mass index were associated with any or ≥10% weight gain. By week 48, 4.6% gained ≥10% weight (6.4% of switch and 2.2% of SBR), the greatest risk was with switch from efavirenz (EFV) to rilpivirine (RPV) or elvitegravir/cobicistat and switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF). Switch from abacavir to TAF was associated with less weight gain than switch from TDF to TAF and was not associated with increased risk for ≥10% weight gain. CONCLUSIONS: Moderate weight gain after ART switch was common and usually plateaued by 48 weeks. Baseline ART was a predictor of post-switch weight gain; participants who switched off of EFV and TDF had the greatest weight gain. The biological mechanisms that underlie the differential effects of switching ART agents on weight and associated clinical implications require further study.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Erlandson KM, Carter CC, Melbourne K, et al. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. Clin Infect Dis. 2021. PMID: 33987636. doi:10.1093/cid/ciab444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。